TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04210700

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block
Description: A linear ultrasound transducer is placed in a sagittal plane to identify the anterior superior iliac spine. By sliding the transducer medially, the fascia iliaca and abdominal internal oblique, sartorius, and iliopsoas muscles are identified. After identifying the bow-tie sign, a 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from caudal to cephalad until the needle tip penetrate the fascia iliaca. After negative aspiration, 0.35% ropivacaine 30mL with 1:400,000 epinephrine will be injected to separate the fascia iliaca and the iliacus muscle.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pericapsular nerve group block
Description: A curvilinear ultrasound transducer is initially place on the anterior inferior iliac spine and then aligned to the iliopubic eminence by rotating around 45 degree. In this view, the iliopubic eminence, iliapsoas muscle and tendon, pectineus muscle, femoral artery and vein will be identified. A 23-gauge needle (7mm, Nipro, Japan) is inserted in plane from lateral to medial until the needle tip in the musculofascial plane between the psoas tendon anteriorly and the pubic ramus posteriorly. After negative aspiration, 0.35% ropivacaine 20mL with 1:400,000 epinephrine will be injected.
Study: NCT03456843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: To demonstrate at least 30% improvement in FFS at 2 years after randomization with the power of 90% and error of 5% on a one-sided exponential MLE test.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy
Description: Undergo cytoreductive radical prostatectomy
Study: NCT00397072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZK 219477
Study: NCT03008031

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CESM with a reduced dose of contrast agent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CESM with a reduced dose of contrast agent

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CESM with a reduced dose of contrast agent
Study: NCT00572156

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NutropinAq® (Somatropin [rDNA origin])
Description: rhGH (Somatropin) 45µg/kg once daily injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Description: rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Description: rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])
Description: rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
Study: NCT01459679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KXL System (15 mW/cm2)
Description: UVA irradiation for 8 minutes at 15 mW/cm2

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KXL System (30 mW/cm2)
Description: UVA irradiation for 4 minutes at 30 mW/cm2
Study: NCT01057316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Formula PTX Stent - Dose 3
Description: Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
Study: NCT01244568

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prostate cancer treatment DESI
Description: DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
Study: NCT02832687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. \<50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 100mL of normal saline every 4 hours to a maximum administration of 400mL
Study: NCT01143259

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvimopam
Description: The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 300 mg Polyethylene
Description: The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
Study: NCT00099983

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02641080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
Study: NCT01459679

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KXL System (45 mW/cm2)
Description: UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin ophthalmic solution
Description: Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
Study: NCT00003166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bryostatin 1
Description: Given IV
Study: NCT02641080

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Portable Compression Device
Description: If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
Study: NCT00003166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT03464682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 10mg
Description: HS-25 10mg 1tablet add placebo of HS-25 1 tablet, placebo of Atorvastatin 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 10mg combination with Atorvastatin
Description: HS-25 10mg 1 tablet , Atorvastatin 10mg 1 tablet, Placebo of HS-25 1 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 20mg combination with Atorvastatin
Description: HS-25 10mg 2 tablets, Atorvastatin 10mg 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10mg
Description: Atorvastatin 10mg 1 tablet, placebo of HS-25 2 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-25 20mg
Description: HS-25 10mg 2 tablets, placebo of Atorvastatin 1 tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebe of HS-25 and Atorvastatin
Description: Placebe of HS-25 2 tablets, Placebo of Atorvastatin 1 tablets
Study: NCT02752997

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacist discharge medication services
Description: Included in arm descriptions
Study: NCT00463450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gynodian® Depot (BAY86-5032)
Description: Injection monthly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAY86-4980
Description: orally
Study: NCT00066092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 12 mg
Description: Pegfilgrastim 12 mg given once for PBPC mobilization

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Filgrastim given daily for PBPC mobilization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegfilgrastim 6 mg
Description: Pegfilgrastim 6 mg given once for PBPC mobilization
Study: NCT02197923

Intervention type: PROCEDURE
Intervention: Myometrial biopsy
Description: transvaginal ultrasound guided biopsy of the myometria

Intervention type: PROCEDURE
Intervention: Myometrial biopsy
Description: transvaginal ultrasound guided biopsy of the myometria

Intervention type: PROCEDURE
Intervention: endometrial biopsy
Description: transcervical endometrial biopsy

Intervention type: PROCEDURE
Intervention: endometrial biopsy
Description: transcervical endometrial biopsy
Study: NCT03305679

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Direct provisional technique
Description: The method of implantation will be accomplished directly.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Indirect Provisional technique
Description: The method of implantation will be accomplished indirectly.
Study: NCT01979653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine alone or dexmedetomidine + midazolam

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine alone or dexmedetomidine + midazolam
Study: NCT00150631

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Candesartan
Description: placebo controlled double blind
Study: NCT00835406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alendronate Sodium Tablets 70mg
Description: 1 x 70mg, single dose fasting

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamax® Tablets 70mg
Description: 1 x 70 mg, single dose fasting
Study: NCT00663936

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-817MA
Description: 224 mg T-817 MA once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo once daily
Study: NCT01678326

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-Rendezvous or direct intervention

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced ERCP Biliary Access Techniques
Study: NCT03011216

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive emotional cognitive control training
Description: Is supposed to train ability to continuously update emotional material in working memory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Adaptive non-emotional feature match task
Description: Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
Study: NCT03443466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural electrical stimulation (EES)
Description: Using loss of resistance technique and electrical stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Loss of resistance (LOR)
Description: Using loss of resistance technique only
Study: NCT00127673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline
Description: The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include 10 weekly sessions of individual cognitive behavioral therapy.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Description: CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
Study: NCT00661063

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: ketamine 150 mcg/g bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: vehicle gel
Description: bid - 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine + clonidine
Description: ketamine 150mcg/g + clonidine 1% gel bid 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine gel 1%
Description: bid 12 weeks
Study: NCT00003166

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00118222

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: porfimer sodium
Description: All patients receive porfimer sodium IV.
Study: NCT01607099

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compatibility
Description: Patients asses the compatibility of the bowel cleansing procedure
Study: NCT02473913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Thistle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02371278

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Leucine
Description: 5 g leucine with sucrose and maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Leucine
Description: 5 g leucine with sucrose and maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 5 g glycine with sucrose and maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 5 g glycine with sucrose and maltodextrin
Study: NCT04456296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aveed Injectable Product
Description: Testosterone undecanoate administered by intramuscular injections.
Study: NCT02582905

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active comparators in appearance.
Study: NCT04456296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fortesta
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim
Description: Testosterone gel administered topically. The daily dose of the study drug will be titrated for each participant, according to approved dosage and administration instructions, until the circulating testosterone concentrations of the participant reaches normal concentrations (300-1000 ng/dL).
Study: NCT00067808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 10 mg/m\^2 by vein over 1 hour daily for 10 days
Study: NCT02582905

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline
Description: Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnenolone
Description: Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
Study: NCT02578524

Intervention type: OTHER
Intervention: Survey

Intervention type: OTHER
Intervention: Survey
Study: NCT03578900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeros

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeros

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeros

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xeros

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citric Acid based Mouthwash
Study: NCT03791398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 1 ONC201 625mg
Description: ONC201 625mg + Nivolumab 240mg IV flat dose
Study: NCT00067808

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 by vein (IV) over 1 hour daily x 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: 20 mg/m2 subcutaneous (SQ) daily x 5 days
Study: NCT02984787

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic total gastrectomy
Description: When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic total gastrectomy
Description: When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
Study: NCT02278822

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low dose oral liposomal glutathione supplementation
Description: Low dose oral liposomal glutathione supplementation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dose oral liposomal glutathione supplementation
Description: High dose oral liposomal glutathione supplementation
Study: NCT03791398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose level 2 ONC201 500mg
Description: ONC201 500mg + Nivolumab 240mg IV flat dose
Study: NCT00118222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: All patients receive porfimer sodium IV.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adjuvant therapy
Description: All patients receive porfimer sodium IV.
Study: NCT01844908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Study: NCT04246099

Intervention type: OTHER
Intervention: Post-operative care
Description: Retrospective collection of clinical data recorded in the electronic medical record.~The following variables were continuously recorded in the institutional database: age, gender, body weight, height, personal medical history, American Society of Anesthesiologists (ASA) score, type of thoracic surgery, the duration of surgery, duration of anesthesia (from intubation to extubation), the duration of PACU stay, the need for morphine titration, epinephrine, norepinephrine.~For data at day 30, the vast majority of patients were included in the enhanced recovery program and as such benefited from a consultation at 1 month with a coordination nurse who collected data on post-operative pain in a standardized manner.~All data was extracted from investigators institutional database and collected by a physician who was not involved in the care of the study patients.
Study: NCT00118222

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Description: All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
Study: NCT03507868

Intervention type: PROCEDURE
Intervention: Nonsurgical periodontal therapy
Description: Nonsurgical periodontal therapy includes oral hygiene education and scaling and root planning approaches to eliminate microbial dental plaque that is the primary etiology of periodontal diseases.